News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cerus Corporation (CERS) Signs Five-Year Agreement With Belgian Red Cross Flanders For The INTERCEPT Blood System For Platelets


5/29/2014 9:07:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that the Belgian Red Cross Flanders (RC-F) has signed a five-year agreement to purchase the INTERCEPT Blood System for platelets. RC-F is one of two major Red Cross blood services in Belgium, and supplies approximately 37,000 platelet components to the northern, or Flemish, region of Belgium.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES